Literature DB >> 20181800

Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

Ming Ruan1, Larry Pederson, Elizabeth W Bradley, Ana-Maria Bamberger, Merry Jo Oursler.   

Abstract

Local release of TGF-beta during times of high bone turnover leads to elevated levels within the bone microenvironment, and we have shown that TGF-beta suppresses osteoclast apoptosis. Therefore, understanding the influences of TGF-beta on bone resorbing osteoclasts is critical to the design of therapies to reduce excess bone loss. Here we investigated the mechanisms by which TGF-beta sustains suppression of osteoclast apoptosis. We found TGF-beta rapidly increased leukemia inhibitory factor (LIF) expression and secretion by phosphorylated mothers against decapentaplegic-dependent and -independent signaling pathways. TGF-beta also induced suppressor of cytokine signaling 3 (SOCS3) expression, which was required for TGF-beta or LIF to promote osteoclast survival by. Blocking LIF or SOCS3 blocked TGF-beta promotion of osteoclast survival, confirming that LIF and SOCS3 expression are necessary for TGF-beta-mediated suppression of osteoclast apoptosis. Investigation of the mechanisms by which LIF promotes osteoclast survival revealed that LIF-induced expression of Bcl-X(L) and repressed Bcl-2 interacting domain expression by activating MAPK kinase, AKT, and nuclear factor-kappaB pathways. Suppression of Janus kinase/signal transducer and activator of transcription signaling further increased Bcl-X(L) expression and enhanced osteoclast survival, supporting that this pathway is not involved in prosurvival effects of TGF-beta and LIF. These data show that TGF-beta coordinately induces LIF and SOCS3 to promote prosurvival signaling. This alters the ratio of prosurvival Bcl2 family member Bcl-X(L) to proapoptotic family member Bcl-2 interacting domain, leading to prolonged osteoclast survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181800      PMCID: PMC2850239          DOI: 10.1210/en.2009-0813

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  53 in total

1.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Authors:  Anne Gingery; Elizabeth W Bradley; Larry Pederson; Ming Ruan; Nikki J Horwood; Merry Jo Oursler
Journal:  Exp Cell Res       Date:  2008-06-13       Impact factor: 3.905

2.  Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic.

Authors:  Yang Lu; Satoru Fukuyama; Ryoko Yoshida; Takashi Kobayashi; Kazuko Saeki; Hiroshi Shiraishi; Akihiko Yoshimura; Giichi Takaesu
Journal:  J Biol Chem       Date:  2006-10-06       Impact factor: 5.157

Review 3.  Transforming growth factor beta1, bone connection.

Authors:  Reem A Kanaan; Lama A Kanaan
Journal:  Med Sci Monit       Date:  2006-07-12

4.  Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3.

Authors:  Helena Slaets; Debora Dumont; Joris Vanderlocht; Jean-Paul Noben; Pierre Leprince; Johan Robben; Jerome Hendriks; Piet Stinissen; Niels Hellings
Journal:  Proteomics       Date:  2008-03       Impact factor: 3.984

5.  Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia.

Authors:  Aline Bozec; Latifa Bakiri; Astrid Hoebertz; Robert Eferl; Arndt F Schilling; Vukoslav Komnenovic; Harald Scheuch; Matthias Priemel; Colin L Stewart; Michael Amling; Erwin F Wagner
Journal:  Nature       Date:  2008-06-11       Impact factor: 49.962

6.  Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.

Authors:  Mitsuru Futakuchi; Kalyan C Nannuru; Michelle L Varney; Anguraj Sadanandam; Kimihisa Nakao; Kiyofumi Asai; Tomoyuki Shirai; Shin-ya Sato; Rakesh K Singh
Journal:  Cancer Sci       Date:  2008-11-25       Impact factor: 6.716

7.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

Authors:  Silvia Peñuelas; Judit Anido; Rosa M Prieto-Sánchez; Gerard Folch; Ignasi Barba; Isabel Cuartas; David García-Dorado; M Antonia Poca; Juan Sahuquillo; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

8.  Leukemia inhibitory factor promotes olfactory sensory neuronal survival via phosphoinositide 3-kinase pathway activation and Bcl-2.

Authors:  Cheil Moon; Bridget Q Liu; So Yeun Kim; Esther J Kim; Yun Ju Park; Joo-Yeon Yoo; Hyung Soo Han; Yong Chul Bae; Gabriele V Ronnett
Journal:  J Neurosci Res       Date:  2009-04       Impact factor: 4.164

9.  Transforming growth factor-beta enables NFATc1 expression during osteoclastogenesis.

Authors:  S W Fox; K E Evans; A C Lovibond
Journal:  Biochem Biophys Res Commun       Date:  2007-12-03       Impact factor: 3.575

10.  Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.

Authors:  Khalid S Mohammad; Carol G Chen; Guive Balooch; Elizabeth Stebbins; C Ryan McKenna; Holly Davis; Maria Niewolna; Xiang Hong Peng; Daniel H N Nguyen; Sophi S Ionova-Martin; John W Bracey; William R Hogue; Darren H Wong; Robert O Ritchie; Larry J Suva; Rik Derynck; Theresa A Guise; Tamara Alliston
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

View more
  16 in total

1.  Extensive mannose phosphorylation on leukemia inhibitory factor (LIF) controls its extracellular levels by multiple mechanisms.

Authors:  Jarrod Barnes; Jae-Min Lim; Anne Godard; Frédéric Blanchard; Lance Wells; Richard Steet
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

Review 2.  Inflammation as death or life signal in diabetic fracture healing.

Authors:  Tamás Roszer
Journal:  Inflamm Res       Date:  2010-09-16       Impact factor: 4.575

Review 3.  Novel insights into the coupling of osteoclasts and resorption to bone formation.

Authors:  Margaret M Durdan; Ruth D Azaria; Megan M Weivoda
Journal:  Semin Cell Dev Biol       Date:  2021-10-30       Impact factor: 7.727

4.  Glucagon-like peptide 2 decreases osteoclasts by stimulating apoptosis dependent on nitric oxide synthase.

Authors:  Yi Lu; Dongdong Lu; Yu Hu
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

5.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

6.  Thrombospondin-1 inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF-β activation.

Authors:  Kimberly Bailey Dubose; Majd Zayzafoon; Joanne E Murphy-Ullrich
Journal:  Biochem Biophys Res Commun       Date:  2012-05-11       Impact factor: 3.575

7.  Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.

Authors:  Margarita Calvo; Ning Zhu; John Grist; Zhenzhong Ma; Jeffrey A Loeb; David L H Bennett
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

Review 8.  Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology.

Authors:  Dawn Mikelonis; Cheryl L Jorcyk; Ken Tawara; Julia Thom Oxford
Journal:  Orphanet J Rare Dis       Date:  2014-03-12       Impact factor: 4.123

Review 9.  Role of suppressors of cytokine signaling 3 in bone inflammatory responses.

Authors:  Anqi Gao; Thomas E Van Dyke
Journal:  Front Immunol       Date:  2014-01-10       Impact factor: 7.561

10.  STAT3 modulates cigarette smoke-induced inflammation and protease expression.

Authors:  Patrick Geraghty; Anne E Wyman; Itsaso Garcia-Arcos; Abdoulaye J Dabo; Sonya Gadhvi; Robert Foronjy
Journal:  Front Physiol       Date:  2013-10-01       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.